Beatriz Álvarez, Angel Montero, Jeannette Valero, Mercedes López, Raquel Ciérvide, Ovidio Hernando, Emilio Sánchez, Miguel Angel de la Casa, Xin Chen-Zhao, Mariola García-Aranda, Ana Martinez, Rosa Alonso, Miguel Sánchez, Pedro Fernández-Letón, Carmen Rubio
{"title":"实施肌肉骨骼疼痛疾病的低剂量放射治疗计划:提示,技巧和临床研究人员的要点。","authors":"Beatriz Álvarez, Angel Montero, Jeannette Valero, Mercedes López, Raquel Ciérvide, Ovidio Hernando, Emilio Sánchez, Miguel Angel de la Casa, Xin Chen-Zhao, Mariola García-Aranda, Ana Martinez, Rosa Alonso, Miguel Sánchez, Pedro Fernández-Letón, Carmen Rubio","doi":"10.1007/s12094-025-03936-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Painful musculoskeletal disorders (PMDs) represent an increasing public health concern, particularly among aging populations. When conservative therapies prove insufficient, low-dose radiotherapy (LDRT) has emerged as a non-invasive and effective treatment alternative. Despite growing clinical evidence supporting its efficacy, LDRT remains underutilized due to persistent skepticism and the absence of standardized clinical guidelines.</p><p><strong>Materials and methods: </strong>This review synthesizes current evidence on the use of LDRT for PMDs, focusing on its biological mechanisms, optimal dosing regimens, clinical efficacy, and safety profile. Attention is given to dose fractionation strategies, timing of re-irradiation, and technological advancements that enhance treatment precision.</p><p><strong>Results: </strong>LDRT provides pain relief in 60-90% of treated cases, with the most favorable results achieved using fraction doses between 0.3 and 0.7 Gy. Its anti-inflammatory effects are mediated through immune modulation, reduced proinflammatory cytokine expression, and promotion of tissue repair. Re-irradiation performed 10-12 weeks after the initial cycle may be beneficial in patients experiencing symptom persistence or recurrence. Long-term follow-up data confirm sustained efficacy and indicate a minimal risk of radiation-induced malignancies in older adults.</p><p><strong>Conclusion: </strong>LDRT is a safe and effective treatment option for PMDs, especially in patients unresponsive to conventional therapies. To facilitate its broader adoption, this review underscores key clinical evidence and proposes practical considerations for integrating LDRT into multidisciplinary pain management protocols.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4020-4030"},"PeriodicalIF":2.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Implementing a low-dose radiation therapy program for musculoskeletal pain disorders: tips, tricks, and essentials for clinical researchers.\",\"authors\":\"Beatriz Álvarez, Angel Montero, Jeannette Valero, Mercedes López, Raquel Ciérvide, Ovidio Hernando, Emilio Sánchez, Miguel Angel de la Casa, Xin Chen-Zhao, Mariola García-Aranda, Ana Martinez, Rosa Alonso, Miguel Sánchez, Pedro Fernández-Letón, Carmen Rubio\",\"doi\":\"10.1007/s12094-025-03936-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Painful musculoskeletal disorders (PMDs) represent an increasing public health concern, particularly among aging populations. When conservative therapies prove insufficient, low-dose radiotherapy (LDRT) has emerged as a non-invasive and effective treatment alternative. Despite growing clinical evidence supporting its efficacy, LDRT remains underutilized due to persistent skepticism and the absence of standardized clinical guidelines.</p><p><strong>Materials and methods: </strong>This review synthesizes current evidence on the use of LDRT for PMDs, focusing on its biological mechanisms, optimal dosing regimens, clinical efficacy, and safety profile. Attention is given to dose fractionation strategies, timing of re-irradiation, and technological advancements that enhance treatment precision.</p><p><strong>Results: </strong>LDRT provides pain relief in 60-90% of treated cases, with the most favorable results achieved using fraction doses between 0.3 and 0.7 Gy. Its anti-inflammatory effects are mediated through immune modulation, reduced proinflammatory cytokine expression, and promotion of tissue repair. Re-irradiation performed 10-12 weeks after the initial cycle may be beneficial in patients experiencing symptom persistence or recurrence. Long-term follow-up data confirm sustained efficacy and indicate a minimal risk of radiation-induced malignancies in older adults.</p><p><strong>Conclusion: </strong>LDRT is a safe and effective treatment option for PMDs, especially in patients unresponsive to conventional therapies. To facilitate its broader adoption, this review underscores key clinical evidence and proposes practical considerations for integrating LDRT into multidisciplinary pain management protocols.</p>\",\"PeriodicalId\":50685,\"journal\":{\"name\":\"Clinical & Translational Oncology\",\"volume\":\" \",\"pages\":\"4020-4030\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-025-03936-8\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03936-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Implementing a low-dose radiation therapy program for musculoskeletal pain disorders: tips, tricks, and essentials for clinical researchers.
Introduction: Painful musculoskeletal disorders (PMDs) represent an increasing public health concern, particularly among aging populations. When conservative therapies prove insufficient, low-dose radiotherapy (LDRT) has emerged as a non-invasive and effective treatment alternative. Despite growing clinical evidence supporting its efficacy, LDRT remains underutilized due to persistent skepticism and the absence of standardized clinical guidelines.
Materials and methods: This review synthesizes current evidence on the use of LDRT for PMDs, focusing on its biological mechanisms, optimal dosing regimens, clinical efficacy, and safety profile. Attention is given to dose fractionation strategies, timing of re-irradiation, and technological advancements that enhance treatment precision.
Results: LDRT provides pain relief in 60-90% of treated cases, with the most favorable results achieved using fraction doses between 0.3 and 0.7 Gy. Its anti-inflammatory effects are mediated through immune modulation, reduced proinflammatory cytokine expression, and promotion of tissue repair. Re-irradiation performed 10-12 weeks after the initial cycle may be beneficial in patients experiencing symptom persistence or recurrence. Long-term follow-up data confirm sustained efficacy and indicate a minimal risk of radiation-induced malignancies in older adults.
Conclusion: LDRT is a safe and effective treatment option for PMDs, especially in patients unresponsive to conventional therapies. To facilitate its broader adoption, this review underscores key clinical evidence and proposes practical considerations for integrating LDRT into multidisciplinary pain management protocols.
期刊介绍:
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.